Biogen posts 50% growth in profits

Biogen Idec's first-quarter profits jumped 50 percent to $244 million on higher sales of its multiple sclerosis drug Avonex; revenues grew by a healthy 10 percent to $1.04 billon, and EPS beat analysts' estimates. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.